Enck P, Aziz Q, Barbara G, Farmer A, Fukudo S, Mayer E, Niesler B, Quigley E, Rajilic-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller R. Irritable bowel syndrome (IBS). Nat Rev Dis Primers. 2016;2:16014.
PubMed
PubMed Central
Article
Google Scholar
Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Imren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S, Kellow J, Okeke E, Quigley EM, Schmulson M, Whorwell P, Archampong T, Adibi P, Andresen V, Benninga MA, Bonaz B, Bor S, Fernandez LB, Choi SC, Corazziari ES, Francisconi C, Hani A, Lazebnik L, Lee YY, Mulak A, Rahman MM, Santos J, Setshedi M, Syam AF, Vanner S, Wong RK, Lopez-Colombo A, Costa V, Dickman R, Kanazawa M, Keshteli AH, Khatun R, Maleki I, Poitras P, Pratap N, Stefanyuk O, Thomson S, Zeevenhooven J, Palsson OS. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2020.04.014.
Article
PubMed
Google Scholar
Fukudo S, Kaneko H, Akiho H, Inamori M, Endo Y, Okumura T, Kanazawa M, Kamiya T, Sato K, Chiba T, Furuta K, Yamato S, Arakawa T, Fujiyama Y, Azuma T, Fujimoto K, Mine T, Miura S, Kinoshita Y, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol. 2015;50:11–30.
CAS
PubMed
Article
Google Scholar
Li H, Xing X, Yao L, Li M, Xun Y, Yan P, Yang X, Yang K. Assessment of the quality and content of clinical practice guidelines on irritable bowel syndrome using the AGREE II instrument. Digestion. 2020;101:355–65.
PubMed
Article
Google Scholar
Fukudo S. Stress and visceral pain: focusing on irritable bowel syndrome. Pain. 2013;154(Suppl 1):S63-70.
CAS
PubMed
Article
Google Scholar
Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.
PubMed
Article
Google Scholar
Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel disorders. Gastroenterology. 2016;150:1393–407.
Article
Google Scholar
Yoshida M, Kinoshita Y, Watanabe M, Sugano K. JSGE clinical practice guidelines 2014: standards, methods, and process of developing the guidelines. J Gastroenterol. 2015;50:4–10.
PubMed
Article
Google Scholar
Qaseem A, Snow V, Owens DK, Shekelle P. Clinical Guidelines Committee of the American College of Physicians. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med. 2010;153:194–9.
PubMed
Article
Google Scholar
Qaseem A, Kansagara D, Lin JS, Mustafa RA, Wilt TJ. Clinical Guidelines Committee of the American College of Physicians. The development of clinical guidelines and guidance statements by the clinical guidelines committee of the American College of Physicians: update of methods. Ann Intern Med. 2019;170:863–70.
PubMed
Article
Google Scholar
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–21.
PubMed
Article
Google Scholar
Kanazawa M, Endo Y, Whitehead WE, et al. Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress. Dig Dis Sci. 2004;49:1046–53.
PubMed
Article
Google Scholar
Kubo M, Fujiwara Y, Shiba M, et al. Differences between risk factors among irritable bowel syndrome subtypes in Japanese adults. Neurogastroenterol Motil. 2011;23:249–54.
CAS
PubMed
Article
Google Scholar
Barbara G, Grover M, Bercik P, et al. Rome Foundation working team report on post-infection irritable bowel syndrome. Gastroenterology. 2019;156(46–58):e7.
Google Scholar
Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:535–44.
CAS
PubMed
Article
Google Scholar
Porter CK, Gormley R, Tribble DR, Cash BD, Riddle MS, Porter CK. The incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol. 2011;106:130–8.
PubMed
Article
Google Scholar
Longstreth GF, Hawkey CJ, Mayer EA, et al. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment Pharmacol Ther. 2001;15:959–64.
CAS
PubMed
Article
Google Scholar
Whitehead WE, Crowell MD, Robinson JC, et al. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut. 1992;33:825–30.
CAS
PubMed
PubMed Central
Article
Google Scholar
Fukudo S, Suzuki J. Colonic motility, autonomic function, and gastrointestinal hormones under psychological stress on irritable bowel syndrome. Tohoku J Exp Med. 1987;151:373–85.
CAS
PubMed
Article
Google Scholar
Elsenbruch S, Rosenberger C, Bingel U, et al. Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology. 2010;139:1310–9.
PubMed
Article
Google Scholar
Kano M, Muratsubaki T, Morishita J, et al. Influence of uncertain anticipation on brain responses to aversive rectal distension in patients with irritable bowel syndrome. Psychosom Med. 2017;79:988–99.
PubMed
Article
Google Scholar
Aizawa E, Sato Y, Kochiyama T, et al. Altered cognitive function of prefrontal cortex during error feedback in patients with irritable bowel syndrome, based on fMRI and dynamic causal modeling. Gastroenterology. 2012;143:1188–98.
PubMed
Article
Google Scholar
Parker CH, Naliboff BD, Shih W, et al. Negative events during adulthood are associated with symptom severity and altered stress response in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2019;17:2245–52.
PubMed
PubMed Central
Article
Google Scholar
Ng QX, Soh AYS, Loke W, et al. Systematic review with meta-analysis: the association between post-traumatic stress disorder and irritable bowel syndrome. J Gastroenterol Hepatol. 2019;34:68–73.
PubMed
Article
Google Scholar
Pittayanon R, Lau JT, Yuan Y, et al. Gut microbiota in patients with irritable bowel syndrome - A systematic review. Gastroenterology. 2019;157:97–108.
PubMed
Article
Google Scholar
Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:512–9.
CAS
PubMed
Google Scholar
Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63:744–52.
PubMed
Article
CAS
Google Scholar
Fritscher-Ravens A, Pflaum T, Mösinger M, et al. Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin E. Gastroenterology. 2019;157(109–118):e5.
Google Scholar
Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2015;42:3–11.
CAS
PubMed
Article
Google Scholar
Vijayvargiya P, Busciglio I, Burton D, et al. Bile acid deficiency in a subgroup of patients with irritable bowel syndrome with constipation based on biomarkers in serum and fecal samples. Clin Gastroenterol Hepatol. 2018;16:522–7.
CAS
PubMed
Article
Google Scholar
Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology. 2011;140:91–100.
PubMed
Article
Google Scholar
Seminowicz DA, Labus JS, Bueller JA, et al. Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology. 2010;139:48–57.
PubMed
Article
Google Scholar
Blankstein U, Chen J, Diamant NE, et al. Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. Gastroenterology. 2010;138:1783–9.
Article
PubMed
Google Scholar
Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, Nishida A, Haruma K. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;150(358–366):e8.
Google Scholar
Kanazawa M, Watanabe S, Tana C, et al. Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2011;23:754-e332.
CAS
PubMed
Article
Google Scholar
Mayer EA, Berman S, Derbyshire SW, et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther. 2002;16:1357–66.
CAS
PubMed
Article
Google Scholar
Kułak-Bejda A, Bejda G, Waszkiewicz N. Antidepressants for irritable bowel syndrome: a systematic review. Pharmacol Rep. 2017;69:1366–79.
PubMed
Article
CAS
Google Scholar
Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut. 1998;42:845–9.
CAS
PubMed
PubMed Central
Article
Google Scholar
Kano M, Muratsubaki T, Van Oudenhove L, et al. Altered brain and gut responses to corticotropin-releasing hormone (CRH) in patients with irritable bowel syndrome. Sci Rep. 2017;7:12425.
PubMed
PubMed Central
Article
CAS
Google Scholar
Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006;130:304–11.
CAS
PubMed
Article
Google Scholar
Tanaka Y, Kanazawa M, Kano M, et al. Differential activation in amygdala and plasma noradrenaline during colorectal distention by administration of corticotropin-releasing hormone between healthy individuals and patients with irritable bowel syndrome. PLoS ONE. 2016;11:e0157347.
PubMed
PubMed Central
Article
CAS
Google Scholar
Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut. 2004;53:958–64.
CAS
PubMed
PubMed Central
Article
Google Scholar
Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150:1262–79.
Article
Google Scholar
Koloski NA, Jones M, Kalantar J, et al. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012;61:1284–90.
CAS
PubMed
Article
Google Scholar
Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121:799–804.
CAS
PubMed
Article
Google Scholar
Adeyemo MA, Spiegel BM, Chang L. Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? Aliment Pharmacol Ther. 2010;32:738–55.
CAS
PubMed
PubMed Central
Article
Google Scholar
Villani AC, Lemire M, Thabane M, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138:1502–13.
CAS
PubMed
Article
Google Scholar
Saito YA, Strege PR, Tester DJ, et al. Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. Am J Physiol Gastrointest Liver Physiol. 2009;296:G211–8.
CAS
PubMed
Article
Google Scholar
Czogalla B, Schmitteckert S, Houghton LA, et al. A meta-analysis of immunogenetic case-control association studies in irritable bowel syndrome. Neurogastroenterol Motil. 2015;27:717–27.
CAS
PubMed
Article
Google Scholar
Ek WE, Reznichenko A, Ripke S, et al. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut. 2015;64:1774–82.
CAS
PubMed
Article
Google Scholar
Fukudo S, Kanazawa M, Mizuno T, et al. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. Neuroimage. 2009;47:946–51.
CAS
PubMed
Article
Google Scholar
Kilpatrick LA, Mayer EA, Labus JS, et al. Serotonin transporter gene polymorphism modulates activity and connectivity within an emotional arousal network of healthy men during an aversive visceral stimulus. PLoS ONE. 2015;10:e0123183.
PubMed
PubMed Central
Article
CAS
Google Scholar
Zhu Y, Zheng G, Hu Z. Association between SERT insertion/deletion polymorphism and the risk of irritable bowel syndrome: a meta-analysis based on 7039 subjects. Gene. 2018;679:133–7.
CAS
PubMed
Article
Google Scholar
Sasaki A, Sato N, Suzuki N, et al. Associations between single-nucleotide polymorphisms in corticotropin-releasing hormone-related genes and irritable bowel syndrome. PLoS ONE. 2016;11:e0149322.
PubMed
PubMed Central
Article
CAS
Google Scholar
Sato N, Suzuki N, Sasaki A, et al. Corticotropin-releasing hormone receptor 1 gene variants in irritable bowel syndrome. PLoS ONE. 2012;7:e42450.
CAS
PubMed
PubMed Central
Article
Google Scholar
Komuro H, Sato N, Sasaki A, et al. Corticotropin-releasing hormone receptor 2 gene variants in irritable bowel syndrome. PLoS ONE. 2016;11:e0147817.
PubMed
PubMed Central
Article
CAS
Google Scholar
Orand A, Naliboff B, Gadd M, et al. Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response. Psychoneuroendocrinology. 2016;73:133–41.
CAS
PubMed
PubMed Central
Article
Google Scholar
Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology. 2005;128:580–9.
PubMed
Article
Google Scholar
Törnblom H, Van Oudenhove L, Sadik R, et al. Colonic transit time and IBS symptoms: what’s the link? Am J Gastroenterol. 2012;107:754–60.
PubMed
Article
Google Scholar
Lam C, Chaddock G, Marciani Laurea L, et al. Distinct abnormalities of small bowel and regional colonic volumes in subtypes of irritable bowel syndrome revealed by MRI. Am J Gastroenterol. 2017;112:346–55.
PubMed
Article
Google Scholar
Pozuelo M, Panda S, Santiago A, et al. Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome. Sci Rep. 2015;5:12693.
CAS
PubMed
PubMed Central
Article
Google Scholar
Kanazawa M, Palsson OS, Thiwan SI, et al. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol. 2008;103:2550–61.
PubMed
Article
Google Scholar
Kim ES, Cheon JH, Park JJ, et al. Colonoscopy as an adjunctive method for the diagnosis of irritable bowel syndrome: focus on pain perception. J Gastroenterol Hepatol. 2010;25:1232–8.
PubMed
Article
Google Scholar
Mizukami T, Sugimoto S, Masaoka T, et al. Colonic dysmotility and morphological abnormality frequently detected in Japanese patients with irritable bowel syndrome. Intest Res. 2017;15:236–43.
PubMed
PubMed Central
Article
Google Scholar
Ishihara S, Yashima K, Kushiyama Y, et al. Prevalence of organic colonic lesions in patients meeting Rome III criteria for diagnosis of IBS: a prospective multi-center study utilizing colonoscopy. J Gastroenterol. 2012;47:1084–90.
PubMed
Article
Google Scholar
Gu HX, Zhang YL, Zhi FC, et al. Organic colonic lesions in 3,332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case: control study. Int J Colorectal Dis. 2011;26:935–40.
PubMed
Article
Google Scholar
Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007;13:175–81.
PubMed
Article
Google Scholar
Dolwani S, Metzner M, Wassell JJ, et al. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther. 2004;20:615–21.
CAS
PubMed
Article
Google Scholar
Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444–54.
CAS
PubMed
Article
Google Scholar
Ford AC, Chey WD, Talley NJ, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med. 2009;169:651–8.
PubMed
Article
Google Scholar
Smalley W, Falck-Ytter C, Carrasco-Labra A, et al. AGA clinical practice guidelines on the laboratory evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D). Gastroenterology. 2019;157:851–4.
PubMed
Article
Google Scholar
Fukunaga M, Ishimura N, Fukuyama C, et al. Celiac disease in non-clinical populations of Japan. J Gastroenterol. 2018;53:208–14.
PubMed
Article
Google Scholar
Wedlake L, A’Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30:707–17.
CAS
PubMed
Article
Google Scholar
Valentin N, Camilleri M, Altayar O, et al. Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis. Gut. 2016;65:1951–9.
CAS
PubMed
Article
Google Scholar
Kusunoki H, Kamada T, Sato M, et al. Ultrasonographic assessment of sigmoid colon in patients with irritable bowel syndrome. Nihon Rinsho. 2006;64:1461–6.
PubMed
Google Scholar
Guliter S, Yilmaz S, Yakaryilmaz F, et al. Evaluation of gallbladder motility in patients with irritable bowel syndrome. Swiss Med Wkly. 2005;135:407–11.
PubMed
Google Scholar
Güçlü M, Pourbagher A, Serin E, et al. Ultrasonographic evaluation of gallbladder functions in patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21:1309–12.
PubMed
Article
Google Scholar
Yuan YZ, Tao RJ, Xu B, et al. Functional brain imaging in irritable bowel syndrome with rectal balloon-distention by using fMRI. World J Gastroenterol. 2003;9:1356–60.
PubMed
PubMed Central
Article
Google Scholar
Song GH, Venkatraman V, Ho KY, Chee MW, Yeoh KG, Wilder-Smith CH. Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls. Pain. 2006;126:79–90.
PubMed
Article
Google Scholar
Guleria A, Karyampudi A, Singh R, et al. Mapping of brain activations to rectal balloon distension stimuli in male patients with irritable bowel syndrome using functional magnetic resonance imaging. J Neurogastroenterol Motil. 2017;23:415–27.
PubMed
PubMed Central
Article
Google Scholar
Lembo AJ, Neri B, Tolley J, et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:834–42.
CAS
PubMed
Article
Google Scholar
Ohman L, Stridsberg M, Isaksson S, et al. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol. 2012;107:440–7.
PubMed
Article
CAS
Google Scholar
El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: natural history of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;19:861–70.
CAS
PubMed
Article
Google Scholar
Nørgaard M, Farkas DK, Pedersen L, et al. Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study. Br J Cancer. 2011;104:1202–6.
PubMed
PubMed Central
Article
Google Scholar
Hsiao CW, Huang WY, Ke TW, et al. Association between irritable bowel syndrome and colorectal cancer: a nationwide population-based study. Eur J Intern Med. 2014;25:82–6.
PubMed
Article
Google Scholar
Faresjo A, Grodzinsky E, Hallert C, et al. Patients with irritable bowel syndrome are more burdened by co-morbidity and worry about serious diseases than healthy controls: eight years follow-up of IBS patients in primary care. BMC Public Health. 2013;13:832.
PubMed
PubMed Central
Article
Google Scholar
Staudacher HM, Whelan K, Irving PM, et al. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet. 2011;24:487–95.
CAS
PubMed
Article
Google Scholar
Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(1399–1407):e2.
Google Scholar
Johannesson E, Simren M, Strid H, et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106:915–22.
PubMed
Article
Google Scholar
Johannesson E, Ringström G, Abrahamsson H, et al. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015;21:600–8.
PubMed
PubMed Central
Article
Google Scholar
Zhou C, Zhao E, Li Y, et al. Exercise therapy of patients with irritable bowel syndrome: a systematic review of randomized controlled trials. Neurogastroenterol Motil. 2019;31:e13461.
PubMed
Article
Google Scholar
Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7:87–92.
CAS
PubMed
Article
Google Scholar
Masamune K, Miwa T, Fukutomi H, et al. Phase III trial of calcium polycarbophil in patients with irritable bowel syndrome: double-blind, randomized, controlled trial comparing trimebutine maleate. Yakuri-to-Chiryou. 1998;26:967–96.
Google Scholar
Bijkerk CJ, de Wit NJ, Muris JW, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154.
CAS
PubMed
PubMed Central
Article
Google Scholar
Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Ford AC. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1367–74.
CAS
PubMed
Article
Google Scholar
Taniyama K, Sano I, Nakayama S, et al. Dual effect of trimebutine on contractility of the guinea pig ileum via the opioid receptors. Gastroenterology. 1991;101:1579–87.
CAS
PubMed
Article
Google Scholar
Lee HT, Kim BJ. Tromebutine as a modulator of gastrointestinal motility. Arch Pharm Res. 2011;34:861–4.
CAS
PubMed
Article
Google Scholar
Kang SH, Jeen YT, Koo JS, et al. Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study. Korean J Gastroenterol. 2013;62:278–87.
PubMed
Article
Google Scholar
Dumitrascu DL, Stanculete M. The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome. Rom J Intern Med. 2006;44:278–80.
Google Scholar
Karabulut GS, Beser OF, Erginoz E, et al. The incidence of irritable bowel syndrome in children using the Rome III criteria and the effect of trimebutine treatment. J Neurogastroenterol Motil. 2013;19:90–3.
PubMed
PubMed Central
Article
Google Scholar
Luttecke K. A three-part controlled trial of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin. 1980;6:437–43.
CAS
PubMed
Article
Google Scholar
Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25:225–46.
CAS
PubMed
Article
Google Scholar
Poynard T, Naveau S, Mory B, et al. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8:499–510.
CAS
PubMed
Article
Google Scholar
Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome cochrane database. Syst Rev. 2011;8:003460.
Google Scholar
Heading R, Bardhan K, Hollerbach S, et al. Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome: a European perspective. Aliment Pharmacol Ther. 2006;24:207–36.
CAS
PubMed
Article
Google Scholar
Cann PA, Read NW, Holdsworth CD. Oral domperidone: double blind comparison with placebo in irritable bowel syndrome. Gut. 1983;24:1135–40.
CAS
PubMed
PubMed Central
Article
Google Scholar
Fielding JF. Domperidone treatment in the irritable bowel syndrome. Digestion. 1982;23:125–7.
CAS
PubMed
Article
Google Scholar
Khalif IL, Quigley EM, Makarchuk PA, et al. Interactions between symptoms and motor visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics). J Gastrointestin Liver Dis. 2009;18:17–22.
PubMed
Google Scholar
Dobrilla G, Imbimbo BP, Piazzi L, et al. Long-term treatment of irritable bowel syndrome with cimetropium bromide: a double-blind placebo contolled clinical trial. Gut. 1990;31:355–8.
CAS
PubMed
PubMed Central
Article
Google Scholar
Batttaglia G, Morselli-Labate AM, Camarri E, et al. Otilonium bromide in irritable bowel syndrome: a double-blinded, placebo-controlled, 15-week study. Aliment Pharmacol Ther. 1998;12:1003–10.
Article
Google Scholar
Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. BMJ. 2009;337:e2313.
Article
Google Scholar
Tack J, Fried M, Houghton LA, et al. Systematic review: the efficacy of treatments for irritable bowel syndrome- a European perspective. Aliment Pharmacol Ther. 2006;24:183–205.
CAS
PubMed
Article
Google Scholar
Brenner DM, Moeller MJ, Chey WD, et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104:1033–49.
CAS
PubMed
Article
Google Scholar
Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59:325–32.
CAS
PubMed
Article
Google Scholar
Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterology. 2009;9:15.
PubMed
PubMed Central
Article
Google Scholar
Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:385–96.
CAS
PubMed
Article
Google Scholar
Silk DBA, Davis A, Vulevic J, et al. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:508–18.
CAS
PubMed
Article
Google Scholar
Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1547–61.
PubMed
Article
Google Scholar
McKenzie YA, Thompson J, Gulia P, et al. British dietetic association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adult (2016 update). J Hum Nur Diet. 2016;29:576–92.
CAS
Article
Google Scholar
Hungin APS, Mitchell CR, Whorwell P, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidence-based international consensus. Aliment Pharmacol Ther. 2018;47:1054–70.
CAS
PubMed
PubMed Central
Article
Google Scholar
Barbara G, Cremon C, Azpiroz F. Probiotics in irritable bowel syndrome: where are we? Neurogastroenterol Motil. 2018;30:e13513.
PubMed
Article
Google Scholar
Ford AC, Harris LA, Jacy BE, et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48:1044–60.
PubMed
Article
Google Scholar
Black CJ, Burr NE, Camilleri M, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut. 2019;69:74–82.
PubMed
Article
CAS
Google Scholar
Zheng Y, Yu T, Tang Y, et al. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2017;12:e0172846.
PubMed
PubMed Central
Article
CAS
Google Scholar
Andresen V, Montori VM, Keller J, et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2008;6:545–55.
CAS
PubMed
PubMed Central
Article
Google Scholar
Cremonini F, Nicandro JP, Atkinson V, et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. 2012;36:437–48.
CAS
PubMed
PubMed Central
Article
Google Scholar
Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2004;99:2195–203.
CAS
PubMed
Article
Google Scholar
Lembo T, Wright RA, Bagby B, et al. Lotronex investigator team. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:2662–70.
CAS
PubMed
Article
Google Scholar
Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161:1733–40.
CAS
PubMed
Article
Google Scholar
Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol. 2007;102:1709–19.
CAS
PubMed
Article
Google Scholar
Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149–59.
CAS
PubMed
Article
Google Scholar
Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355:1035–40.
CAS
PubMed
Article
Google Scholar
Watson ME, Lacey L, Kong S, et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:455–9.
CAS
PubMed
Article
Google Scholar
Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63:1617–25.
CAS
PubMed
Article
Google Scholar
Matsueda K, Harasawa S, Hongo M, et al. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1202–11.
CAS
PubMed
Article
Google Scholar
Fukudo S, Ida M, Akiho H, et al. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2014;12(953–959):e4.
Google Scholar
Fukudo S, Kinoshita Y, Okumura T, et al. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. J Gastroenterol. 2016;51:874–82.
CAS
PubMed
Article
Google Scholar
Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome: a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987;130:77–80.
PubMed
Article
Google Scholar
Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl. 1987;130:81–4.
CAS
PubMed
Article
Google Scholar
Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996;31:463–8.
CAS
PubMed
Article
Google Scholar
Faresjo A, Grodzinsky E, Johansson S, et al. Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care. J Manag Care Pharm. 2008;14:870–7.
PubMed
Article
Google Scholar
Hanauer SB. The role of loperamide in gastrointestinal disorders. Rev Gastroenterol Disord. 2008;8:15–20.
PubMed
Google Scholar
Videlock EJ, Chang L. Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. Gastroenterol Clin North Am. 2007;36:665–85.
PubMed
Article
Google Scholar
Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013;145:329–38.
CAS
PubMed
Article
Google Scholar
Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374:242–53.
CAS
PubMed
Article
Google Scholar
Fernández-Bañares F, Rosinach M, Piqueras M, et al. Randomised clinical trial: colestyramine vs. hydroxypropyl cellulose in patients with functional chronic watery diarrhoea. Aliment Pharmacol Ther. 2015;41:1132–40.
PubMed
Article
CAS
Google Scholar
Camilleri M, Acosta A, Busciglio I, et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41:438–48.
CAS
PubMed
PubMed Central
Article
Google Scholar
Camilleri M, Ford AC. Pharmacotherapy for irritable bowel syndrome. J Clin Med. 2017;6:101.
PubMed Central
Article
CAS
Google Scholar
Li F, Fu T, Tong WD, et al. Lubiprostone is effective in the treatment of chronic idiopathic constipation and irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2016;91:456–68.
PubMed
Article
CAS
Google Scholar
Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012;35:587–99.
CAS
PubMed
Article
Google Scholar
Fukudo S, Miwa H, Nakajima A, et al. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan. Neurogastroenterol Motil. 2018;30:e13444.
PubMed
Article
CAS
Google Scholar
Shah ED, Kim HM, Schoenfeld P. Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis. Am J Gastroenterol. 2018;113:329–38.
CAS
PubMed
PubMed Central
Article
Google Scholar
Black CJ, Burr NE, Quigley EMM, et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018;155:1753–63.
CAS
PubMed
Article
Google Scholar
Bunnett NW. Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract. J Physiol. 2014;592:2943–50.
CAS
PubMed
PubMed Central
Article
Google Scholar
Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:1270–5.
CAS
PubMed
PubMed Central
Article
Google Scholar
Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010;139:1549–58.
CAS
PubMed
Article
Google Scholar
Nakajima A, Seki M, Taniguchi S, et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:537–47.
PubMed
Article
Google Scholar
Nakajima A, Taniguchi S, Kurosu S, et al. Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: post hoc analyses of two phase 3 trials in Japan. Neurogastroenterol Motil. 2019;31:e13571.
CAS
PubMed
PubMed Central
Article
Google Scholar
Choi CH, Kwon JG, Kim SK, et al. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol Motil. 2015;27:705–16.
CAS
PubMed
Article
Google Scholar
Evans BW, Clark WK, Moore DJ, et al. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev. 2007;4:CD03960.
Google Scholar
Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther. 2014;39:239–53.
CAS
PubMed
Article
Google Scholar
Nyberg C, Hendel J, Nielsen OH. The safety of osmotically acting cathartics in colonic cleansing. Nat Rev Gastroenterol Hepatol. 2010;7:557–64.
PubMed
Article
Google Scholar
Belsey JD, Geraint M, Dixon TA. Systematic review and meta-analysis: polyethylene glycol in adults with non-organic constipation. Int J Clin Pract. 2010;64:944–55.
CAS
PubMed
Article
Google Scholar
Mínguez M, López Higueras A, Júdez J. Use of polyethylene glycol in functional constipation and fecal impaction. Rev Esp Enferm Dig. 2016;108:790–806.
PubMed
Google Scholar
Chapman RW, Stanghellini V, Geraint M, et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108:1508–15.
CAS
PubMed
Article
Google Scholar
Khan S. Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol. 2010;7:565–81.
PubMed
Article
Google Scholar
Kamm MA, Mueller-Lissner S, Wald A, et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol. 2011;9:577–83.
CAS
PubMed
Article
Google Scholar
Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105:897–903.
CAS
PubMed
Article
Google Scholar
Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol. 2003;36:386–9.
PubMed
Article
Google Scholar
Alsalimy N, Madi L, Awaisu A. Efficacy and safety of laxatives for chronic constipation in long-term care settings: a systematic review. J Clin Pharm Ther. 2018;43:595–605.
CAS
PubMed
Article
Google Scholar
Xie C, Tang Y, Wang Y, et al. Efficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysis. PLoS ONE. 2015;10:e0127815.
PubMed
PubMed Central
Article
CAS
Google Scholar
Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther. 2010;32:1221–33.
PubMed
Article
Google Scholar
Brennan BP, Fogarty KV, Roberts JL, et al. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol. 2008;24:423–8.
Article
CAS
Google Scholar
Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder: a double-blind placebo-controlled study with mianserin. Scand J Gatroenterol. 1996;31:318–25.
CAS
Article
Google Scholar
Akama F, Mikami K, Watanabe N, Kimoto K, Yamamoto K, Matsumoto H. Efficacy of mirtazapine on irritable bowel syndrome with anxiety and depression: a case study. J Nippon Med Sch. 2018;85:330–3.
PubMed
Article
Google Scholar
Nigam P, Kapoor KK, Rastog CK, et al. Different therapeutic regimens in irritable bowel syndrome. J Assoc Physicians India. 1984;32:1041–4.
CAS
PubMed
Google Scholar
Pace F, Maurano A, Ciacci C, et al. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2010;14:155–62.
CAS
PubMed
Google Scholar
Lan L, Chen YL, Zhang H, et al. Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety. World J Gastroenterol. 2014;20:11422–8.
CAS
PubMed
PubMed Central
Article
Google Scholar
Lackner JM, Jaccard J, Krasner SS, et al. How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. Gastroenterology. 2007;133:433–44.
PubMed
Article
Google Scholar
Moss-Morris R, McAlpine L, Didsbury LP, et al. A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care. Psychol Med. 2010;40:85–94.
CAS
PubMed
Article
Google Scholar
Blanchard EB, Greene B, Scharff L, Schwarz-McMorris SP. Relaxation training as a treatment for irritable bowel syndrome. Biofeedback Self Regul. 1993;18:125–32.
CAS
PubMed
Article
Google Scholar
Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet. 1984;2:1232–4.
CAS
PubMed
Article
Google Scholar
Garland EL, Gaylord SA, Palsson O, et al. Therapeutic mechanisms of a mindfulness-based treatment for IBS: effects on visceral sensitivity, catastrophizing, and affective processing of pain sensations. J Behav Med. 2012;35:591–602.
PubMed
Article
Google Scholar
Shaw G, Srivastava ED, Sadlier M, et al. Stress management for irritable bowel syndrome: a controlled trial. Digestion. 1991;50:36–42.
CAS
PubMed
Article
Google Scholar
Svedlund J, Sjodin I, Ottosson JO, Dotevall G. Controlled study of psychotherapy in irritable bowel syndrome. Lancet. 1983;2:589–92.
CAS
PubMed
Article
Google Scholar
Guthrie E. Brief psychotherapy with patients with refractory irritable bowel syndrome. Br J Psychother. 1991;8:175–88.
Article
Google Scholar
Ford AC, Lacy BE, Harris LA, et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019;114:21–39.
PubMed
Article
Google Scholar
Neff DF, Blanchard EB. A multi-component treatment for irritable bowel syndrome. Behav Ther. 1987;18:70–83.
Article
Google Scholar
Shinozaki M, Kanazawa M, Kano M, et al. Effect of autogenic training on general improvement in patients with irritable bowel syndrome: a randomized controlled trial. Appl Psychophysiol Biofeedback. 2010;35:189–98.
PubMed
Article
Google Scholar
Laird KT, Tanner-Smith EE, Russell AC, et al. Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: a systematic review and meta-analysis. Clin Psychol Rev. 2017;51:142–52.
PubMed
Article
Google Scholar
Oka T, Okumi H, Nishida S, Ito T, Morikiyo S, Kimura Y, Murakami M. JOPM-EBM working team effects of kampo on functional gastrointestinal disorders. Biopsycho Soc Med. 2014;8:5.
Article
Google Scholar
Sasaki D, Uehara S, Hiwatashi N, et al. Clinical Efficacy of Keishi-ka-shakuyaku-to in patients with irritable bowel syndrome: a multicenter collaborative randomized controlled study Rinsho-to-Kenkyu. Japn J Clin Exp Med. 1998;75:1136–52.
Google Scholar
Saitoh K, Kase Y, Ishige A, Komatsu Y, Sasaki H, Shibahara N. Effects of Keishi-ka-shakuyaku-to (Gui-Zhi-Jia-Shao-Yao-Tang) on diarrhea and small intestinal movement. Biol Pharm Bull. 1999;22:87–9.
PubMed
Article
Google Scholar
Kase Y, Hayakawa T, Ishige A, et al. The effects of Hange-shashin-to on the content of prostaglandin E2 and water absorption in the large intestine of rats. Biol Pharm Bull. 1997;20:954–7.
CAS
PubMed
Article
Google Scholar
Bizen A. Clinical efficacy of of hange-shashin-to in diarrhea-predominant irritable bowel syndrome patients with psychological stress: an open-label study Igaku-to- Yakugaku. Med Pharma. 2012;68:127–33.
Google Scholar
Manabe N, Camilleri M, Rao A, et al. Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans. Am J Physiol Gastrointest Liver Physiol. 2010;298:G970-975.
CAS
PubMed
Article
Google Scholar
Nakaya K, Nagura Y, Hasegawa R, et al. Dai-Kenchu-To, a herbal Medicine, attenuates colorectal distention-induced visceromotor responses in rats. J Neurogastroenterol Motil. 2016;22:686–93.
PubMed
PubMed Central
Article
Google Scholar
Nanda R, James R, Smith H, et al. Food intolerance and the irritable bowel syndrome. Gut. 1989;30:1099–104.
CAS
PubMed
PubMed Central
Article
Google Scholar
Kinoshita Y, Oouchi S, Fujisawa T. Eosinophilic gastrointestinal diseases - Pathogenesis, diagnosis, and treatment. Allergol Int. 2019;66:201–4.
Google Scholar
Stefanini GF, Saggioro A, Alvisi V, et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol. 1995;30:535–41.
CAS
PubMed
Article
Google Scholar
Wouters MM, Balemans D, Van Wanrooy S, et al. Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016;150:875–87.
CAS
PubMed
Article
Google Scholar
Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557–63.
PubMed
Article
Google Scholar
Pimentel M. An evidence-based treatment algorithm for IBS based on a bacterial/SIBO hypothesis: part 2. Am J Gastroenterol. 2010;105:1227–30.
PubMed
Article
Google Scholar
Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.
CAS
PubMed
Article
Google Scholar
Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107:28–35.
CAS
PubMed
Article
Google Scholar
Pimentel M, Chatterjee S, Chow EJ, et al. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51:1297–301.
CAS
PubMed
Article
Google Scholar
Cappello G, Spezzaferro M, Grossi L, et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis. 2007;39:530–6.
CAS
PubMed
Article
Google Scholar
Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48:505–12.
PubMed
Article
Google Scholar
Moayyedi P, Andrews CN, MacQueen G, et al. Canadian Association of gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS). J Can Assoc Gastroenterol. 2019;2:6–29.
PubMed
PubMed Central
Article
Google Scholar
Alammar N, Wang L, Saberi B, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med. 2019;19:21.
CAS
PubMed
PubMed Central
Article
Google Scholar
Wu IXY, Wong CHL, Ho RST, et al. Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. Therap Adv Gastroenterol. 2019;12:1756284818820438.
PubMed
PubMed Central
Google Scholar
Zhu L, Ma Y, Ye S, et al. Acupuncture for diarrhoea-predominant irritable bowel syndrome: a network meta-analysis. Evid Based Complement Alternat Med. 2018;1:2890465.
Google Scholar
Chen L, Ilham SJ, Feng B. Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesth Pain Med. 2017;7:e42747.
PubMed
PubMed Central
Article
Google Scholar
Keefer L, Drossman DA, Guthrie E, Simrén M, Tillisch K, Olden K, Whorwell PJ. Centrally mediated disorders of gastrointestinal pain. Gastroenterology. 2016;150:1408–19.
Article
Google Scholar
Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2017;112:365–74.
CAS
PubMed
Article
Google Scholar
Spiegel B, Schoenfeld P, Naliboff B. Systematic review: the prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:183–93.
CAS
PubMed
Article
Google Scholar
García Rodríguez LA, Ruigómez A, Wallander MA, et al. Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand J Gastroenterol. 2000;35:306–11.
PubMed
Article
Google Scholar
Chen CH, Lin CL, Kao CH. Irritable bowel syndrome is associated with an increased risk of dementia: a nationwide population-based study. PLoS ONE. 2016;11:e0144589.
PubMed
PubMed Central
Article
CAS
Google Scholar
Lai SW, Liao KF, Lin CL, Sung FC. Irritable bowel syndrome correlates with increased risk of Parkinson’s disease in Taiwan. Eur J Epidemiol. 2014;29:57–62.
PubMed
Article
Google Scholar
Grover M, Dorn SD, Weinland SR, et al. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci. 2009;54:1284–91.
CAS
PubMed
Article
Google Scholar
Drossman DA. Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol. 2009;104:2897–902.
PubMed
Article
Google Scholar
Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. Am J Gastroenterol. 2014;109:1831–2.
PubMed
Article
Google Scholar
Mizuno S, Masaoka T, Naganuma M, et al. Bifidobacterium-rich fecal donor may be a positive predictor for successful fecal microbiota transplantation in patients with irritable bowel syndrome. Digestion. 2017;96:29–38.
PubMed
Article
Google Scholar
Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3:17–24.
PubMed
Article
Google Scholar
Halkjaer SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67:2107–15.
CAS
PubMed
Article
Google Scholar
Xu D, Chen VL, Steiner CA, et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2019;114:1043–50.
PubMed
PubMed Central
Article
Google Scholar
Drossman DA, Chang L, Bellamy N, et al. Severity in irritable bowel syndrome: a Rome foundation working team report. Am J Gastroenterol. 2011;106:1749–59.
PubMed
Article
Google Scholar
Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–60.
CAS
PubMed
Article
Google Scholar
Drossman DA, McKee DC, Sandler RS, et al. Psychosocial factors in the irritable bowel syndrome: a multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology. 1988;95:701–8.
CAS
PubMed
Article
Google Scholar
Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: a population-based study. Gut. 1997;41:394–8.
CAS
PubMed
PubMed Central
Article
Google Scholar
Kaji M, Fujiwara Y, Shiba M, et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol. 2010;25:1151–6.
PubMed
Article
Google Scholar
Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1474–82.
PubMed
Article
Google Scholar
Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140–56.
PubMed
Article
Google Scholar
Fukudo S, Hongo M, Kaneko H, et al. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil. 2011;23:544-e205.
CAS
PubMed
Article
Google Scholar